-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。12ヶ月目標株価を1ドル引き下げ、26ドルとしました。これは、2027年の1株当たり利益（EPS）予想2.24ドル（0.11ドル引き下げ）の約11.6倍に相当します。また、2026年のEPS予想も0.07ドル引き下げ、2.07ドルとしました。KHCが計画していた2社への分割を一時停止するという予想外の発表を受け、2026年は大規模な再投資の年になると見ています。目標は、2027年にKHCを収益性の高い成長軌道に戻すことであり、2026年下半期には回復の兆しが見られると予想されます。競争圧力の激化と、これらの投資が意図したとおりに成果を上げない可能性を考慮すると、見通しにはリスクがあると見ていますが、同社の通期EPS見通しは短期的な期待値を適切に引き下げていると考えています（2026年のコンセンサス予想は過去90日間で18%低下しています）。注目している2つの指標は、配当性向（2026年には約80%になると予想され、過去の平均は50%～60%）とレバレッジ比率（純負債／調整後EBITDA）（現在は約3.0倍で、KHCの長期目標と一致している）です。当社は引き続き「ホールド」のレーティングを維持します。
Related Articles
Australia
CVS Health Increasingly Likely to Reach 3% Medicare Advantage Target Margin in 2028, RBC Says
CVS Health (CVS) is increasingly more likely to reach its 3% Medicare Advantage target margin in 2028, RBC Capital Markets analyst said in a note Wednesday.Analysts said the company's Q1 adjusted earnings "comfortably" beat expectations, driven by "strong" topline growth and a notable improvement in profitability in the Health Care Benefits segment.Medical costs came in below expectations and, while the company maintained its medical benefit ratio guidance for the year, it is increasingly likely to outperform, according to the note.The brokerage raised its 2026 adjusted earnings estimate for the company to $7.41 from $7.10. Analysts surveyed by FactSet expect $7.29.RBC reiterated its outperform rating on the stock and increased its price target to $107 from $93.Price: $87.01, Change: $+0.14, Percent Change: +0.17%
$CVS
Research
Research Alert: CFRA Maintains Strong Buy Rating On Shares Of Trimble Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We increase our target price to $86, from 85, on a forward P/E of 21x our 2027 EPS projection of $4.08, below historical averages. We increase our 2026 EPS projection to $3.59 from $3.52, and lift our 2027 EPS estimate to $4.08 from $4.06. TRMB reported solid Q1 beats with revenue of $939.9M, up 12% Y/Y, led by AECO at 14% organic revenue and ARR growth, Field Systems posting 12% growth, and Transportation & Logistics growing 7% despite freight market headwinds. ARR reached a record $2.435B, up 13% organically, reinforcing business model durability. Non-GAAP operating margin improved 230 bps to 25.9%, while non-GAAP gross margins expanded 180 bps to 71.0%, and we see continued margin expansion as its subscription revenues scale. We note steady execution in its core business, while building AI momentum through new products and partnerships with AI labs. Management reaffirmed its 2027 targets, supporting our positive view, though macro risks warrant monitoring.
$TRMB
Australia
Apollo Global Trades at Lower Discount Versus Peers, RBC Says
Apollo Global Management (APO) shares are trading in-line with historical average multiple and at a lower discount against its peers, RBC Capital Markets said in a Thursday note."We maintain our Sector Perform rating largely driven by relative valuation," the report said.The note said its Q1 performance was characterized by strong fee-related earnings growth, offset by weak spread-related earnings growth, driving a low adjusted net income per share growth.RBC raised its price target to $146 from $139 on rolling forward its valuation and higher estimates.Price: $127.33, Change: $-2.20, Percent Change: -1.70%
$APO